2021: KRAS Cancer Drug Approved

On This Day in Health: May 28, 2021

On May 28, 2021, the U.S. Food and Drug Administration granted accelerated approval to sotorasib, sold as Lumakras, for a defined group of adults with advanced non-small cell lung cancer. Their disease had to carry a KRAS G12C mutation and have been treated with at least one prior systemic therapy. The medicine became the first approved treatment directed at that particular KRAS alteration. This was a specific molecular milestone, not an approval for every KRAS mutation or every cancer. The date marked a new option for patients whose disease had already required treatment and whose tumor testing identified the qualifying feature.

KRAS is involved in signals that regulate cell growth. Certain changes can keep those signals active in ways that help cancer cells survive and multiply. G12C identifies one particular change in the protein, and sotorasib was designed to target it. This precision matters because a drug developed for one alteration cannot automatically be assumed to work against all changes in the same gene. The approval tied the treatment to an FDA-approved test, bringing the diagnostic result into the prescribing decision. It illustrated the practical value of understanding the tumor's biology, alongside its location, stage and the treatments a patient had already received.

The supporting evidence came from the CodeBreaK 100 study, including a group of patients with previously treated KRAS G12C-mutated lung cancer. Investigators measured tumor response and the duration of those responses. A meaningful proportion of participants had tumors shrink, but many did not meet the response definition. Accelerated approval allowed access on the basis of this evidence while requiring additional work to verify clinical benefit. The medicine also carried clinically important risks, including liver toxicity and lung inflammation. An oral targeted treatment remained a serious cancer therapy requiring assessment and monitoring. Tumor shrinkage, longer disease control and a cure are separate outcomes and should not be treated as interchangeable.

The anniversary captures years of research becoming an available treatment for a narrowly identified population. Its significance is strongest when the original boundaries remain visible: the G12C alteration, advanced non-small cell lung cancer and previous systemic treatment. Those details explain both why the decision mattered and why it could not answer every question about KRAS-driven disease. For patients, the milestone added another possible discussion after earlier therapy. For researchers, it demonstrated that a difficult molecular target could support a drug development program reaching approval. Remembering May 28 means recognizing that achievement while keeping the evidence, the remaining uncertainties and the responsibilities of ongoing cancer care in view.